• 1
    Aisenberg AC. Problems in Hodgkin's disease management. Blood. 1999; 93: 761779.
  • 2
    DeVita VTJr,Simon RM,Hubbard SM, et al. Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med. 1980; 92: 587595.
  • 3
    Young RC,Canellos GP,Chabner BA, et al. Patterns of relapse in advanced Hodgkin's disease treated with combination chemotherapy. Cancer. 1978; 42: 10011007.
  • 4
    Jacquillat C,Auclerc G,Desprez-Curely JP, et al. Maladie de Hodgkin aux stades III et IV: succes et echecs du protocole therapeutique H265. Nouv Presse Med. 1979; 8: 25912595.
  • 5
    Colonna P,Andrieu JM,Ghouadni R, et al. Advanced Hodgkin disease (clinical stages IIIB and IV): low relapse rate after brief chemotherapy followed by high-dose total lymphoid irradiation. Am J Hematol. 1989; 30: 121127.
  • 6
    Bonadonna G,Zucali R,Monfardini S, et al. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer. 1975; 36: 252259.
  • 7
    Valagussa P,Santoro A,Kenda R, et al. Second malignancies in Hodgkin's disease: a complication of certain forms of treatment. BMJ. 1980; 280: 216219.
  • 8
    Bonadonna G,Santoro A,Viviani S, et al. Gonadal damage in Hodgkin's disease from cancer chemotherapeutic regimens. Arch Toxicol Suppl. 1984; 7: 140145.
  • 9
    Viviani S,Santoro A,Ragni G, et al. Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVD. Eur J Cancer Clin Oncol. 1985; 21: 601605.
  • 10
    Brusamolino E,Anselmo AP,Klersy C, et al. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher after combined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study. Haematologica. 1998; 83: 812823.
  • 11
    Delwail V,Jais JP,Colonna P, et al. Fifteen-year secondary leukaemia risk observed in 761 patients with Hodgkin's disease prospectively treated by MOPP or ABVD chemotherapy plus high-dose irradiation. Br J Haematol. 2002; 118: 189194.
  • 12
    Andrieu JM,Jais JP,Colonna P, et al. Ten-year results of a strategy combining 3 cycles of ABVD and high-dose extended irradiation for treating Hodgkin's disease at advanced stages. Ann Oncol. 1998; 9: 195203.
  • 13
    Djeridane M,Oudard S,Escoffre-Barbe M, et al. Treatment of patients with advanced or bulky Hodgkin disease with a 12-week doxorubicin, bleomycin, vinblastine, and dacarbazine-like chemotherapy regimen followed by extended-field, full-dose radiotherapy: long-term results of the Groupe Ouest et Est des Leucemies et Autres Maladies de Sang H90-A/B Multicenter Randomized Trial. Cancer. 2002; 95: 21692179.
  • 14
    Carbone PP,Kaplan HS,Musshoff K, et al. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971; 31: 18601861.
  • 15
    Hasenclever D,Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998; 339: 15061514.
  • 16
    Maucort-Boulch D,Djeridane M,Roy P, et al. Predictive and discriminating 3-risk-group prognostic scoring system for staging Hodgkin lymphomas. Cancer. 2007; 109: 256264.
  • 17
    Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988; 16: 11411154.
  • 18
    Canellos GP,Anderson JR,Propert KJ, et al.Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD.N Engl J Med. 1992; 327: 14781484.
  • 19
    Canellos GP,Niedzwiecki D. Long-term follow-up of Hodgkin's disease trial. N Engl J Med. 2002; 346: 14171418.
  • 20
    Duggan DB,Petroni GR,Johnson JL, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol. 2003; 21: 607614.
  • 21
    Gobbi PG,Levis A,Chisesi T, et al. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol. 2005; 23: 91989207.
  • 22
    Aleman BM,Raemaekers JM,Tirelli U, et al. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med. 2003; 348: 23962406.
  • 23
    Ferme C,Sebban C,Hennequin C, et al. Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after 6 cycles of chemotherapy for patients with advanced Hodgkin's disease: results of the Groupe d'etudes des Lymphomes de l'Adulte H89 trial. Blood. 2000; 95: 22462252.
  • 24
    Ferme C,Mounier N,Casasnovas O, et al. Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood. 2006; 107: 46364642.
  • 25
    Glick JH,Young ML,Harrington D, et al. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. J Clin Oncol. 1998; 16: 1926.
  • 26
    Sieber M,Tesch H,Pfistner B, et al. Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin's Lymphoma Study Group HD6 trial. Ann Oncol. 2004; 15: 276282.
  • 27
    Diehl V,Loeffler M,Pfreundschuh M, et al. Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after 6 cycles of alternating chemotherapy in patients with advance Hodgkin's disease. German Hodgkins' Study Group (GHSG). Ann Oncol. 1995; 6: 901910.
  • 28
    Diehl V,Franklin J,Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med. 2003; 348: 23862395.
  • 29
    Hutchings M,Mikhaeel NG,Fields PA, et al. Prognostic value of interim FDG-PET after 2 or 3 cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol. 2005; 16: 11601168.
  • 30
    Hutchings M,Loft A,Hansen M, et al. FDG-PET after 2 cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006; 107: 5259.
  • 31
    DeVita VT,Jr. Late sequelae of treatment of Hodgkin's disease. Curr Opin Oncol. 1997; 9: 428431.
  • 32
    Franklin J,Pluetschow A,Paus M, et al. Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. Ann Oncol. 2006; 17: 17491760.
  • 33
    le Maignan C,Desablens B,Delwail V, et al. Three cycles of adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) or epirubicin, bleomycin, vinblastine, and methotrexate (EBVM) plus extended field radiation therapy in early and intermediate Hodgkin disease: 10-year results of a randomized trial. Blood. 2004; 103: 5866.
  • 34
    Swerdlow AJ,Higgins CD,Smith P, et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst. 2007; 99: 206214.
  • 35
    Gaya AM,Ashford RF. Cardiac complications of radiation therapy. Clin Oncol (R Coll Radiol). 2005; 17: 153159.
  • 36
    Aleman BM,van den Belt-Dusebout AW,De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007; 109: 18781886.
  • 37
    Munker R,Grutzner S,Hiller E, et al. Second malignancies after Hodgkin's disease: the Munich experience. Ann Hematol. 1999; 78: 544554.